融资净买入居前的科创板股 | | 份 | | | | | | --- | --- | --- | --- | --- | --- | | 688050 | 爱博医 疗 | 38801.71 | 2075.53 | 5.65 | -2.92 | | 688772 | 珠海冠 | 30166.08 | 2011.34 | 7.14 | 0.15 | | | 宇 | | | | | | 688777 | 中控技 术 | 144317.84 | 1980.40 | 1.39 | -2.68 | | 688016 | 心脉医 疗 | 56178.80 | 1961.17 | 3.62 | -2.90 | | 688508 | 芯朋微 | 36637.66 | 1864.17 | 5.36 | 0.33 | | 688166 | 博瑞医 药 | 133432.69 | 1584.92 | 1.20 | 10.98 | | 688486 | 龙迅股 份 | 12152.45 | 1494.60 | 14.02 | -12.34 | | 688469 | 芯联集 成 | 69189.36 | 1430.88 | 2.1 1 ...

业绩方面，社保基金持有个股中，一季报净利润同比增长的有35只，净利润增幅最高的是恒玄科技，公 司一季报共实现净利润1.91亿元，同比增幅为590.22%，净利润同比增幅居前的还有炬芯科技、鼎通科 技等，净利润分别增长385.67%、190.12%。 财报季，社保基金持股动向曝光！一季度末社保基金共现身55只个股前十大流通股东榜，新进17只，增 持11只。 证券时报·数据宝统计显示，社保基金最新出现在55只科创板股前十大流通股东名单中，合计持股量2.60 亿股，期末持股市值合计122.91亿元。持股变动显示，新进17只，增持11只，减持16只，11只股持股量 保持不变。新进股中，铁建重工、盟科药业、新相微等持股量居前。 社保基金持有科创板股中，从前十大流通股东名单中社保基金家数来看，社保基金家数最多的是英科再 生，共有4家社保基金出现在前十大流通股东名单中，即易方达基金管理有限公司-社保基金17042组 合、国泰基金管理有限公司-社保基金2103组合、全国社保基金一一二组合、全国社保基金一一一组 合，分别位列公司第四大、第七大、第八大、第十大流通股东，持股量合计为1282.69万股，占流通股 比例为6.89%。 ...

2025年04月29日 晨会纪要 | 国内市场 | | 涨跌幅（%） | | | --- | --- | --- | --- | | 指数 | 收盘 | 1日 | 上周 | | 上证综合指数 | 3288 | -0.20 | 0.56 | | 深证成份指数 | 9855 | -0.62 | 1.38 | | 沪深300指数 | 3782 | -0.14 | 0.38 | | 创业板指数 | 1934 | -0.65 | 1.74 | | 上证国债指数 | 225 | 0.02 | 0.01 | | 上证基金指数 | 6762 | -0.20 | 0.71 | | | | 资料来源:同花顺iFinD | | 其 他 报 告 | 海外市场 | | 涨跌幅（%） | | | --- | --- | --- | --- | | 指数 | 收盘 | 1日 | 上周 | | 中国香港恒生指数 | 21972 | -0.04 | 2.74 | | 中国香港国企指数 | 8080 | 0.00 | 2.32 | | 中国台湾加权指数 | 20034 | 0.81 | 2.46 | | 道琼斯指数 | 40228 | 0.28 ...

Market Overview - The market experienced a slight upward movement last week, with social media engagement gradually declining compared to the previous two weeks[2] - Retail investor net inflow in A-shares was 67.0 billion CNY, a decrease of 16.3 billion CNY from the previous value, placing it at the 23.1% percentile over the past five years[2][30] Fund Management Trends - Public funds are increasingly favoring growth styles, with a focus on sectors such as electronics, electric new energy, and cyclical industries[2][16] - 40 stocks in public fund heavyweights have outperformed, with a rise exceeding 42%, concentrated in electronics, automotive, and pharmaceuticals[21] Retail Investor Behavior - Financing funds saw a net outflow of 1.23 billion CNY, a reduction of 4.34 billion CNY from the previous week, indicating a slowdown in outflows[34] - The number of individual investors participating in financing and securities lending reached 739.7 thousand, reflecting a slight increase of 0.14% from the previous value[34] Social Media Engagement - The viewing of A-share content on Douyin showed a stable user structure, with an increase in the proportion of users from high-tier cities and younger demographics[7] - On Kuaishou, the number of A-share related works decreased by 110, with a drop in views by 1.884 million and interactions down by 57,000, indicating a decline in engagement[11] Market Sentiment - Positive sentiment on Weibo increased significantly due to supportive government measures and better-than-expected economic growth in Q1[13]

A股复盘 | 横盘 / 2025.04.28 今天群友又共贡献了不少段子： 这市场有一种平静的疯感 工具箱打开一看，就剩工具箱了 打个贸易战，把大a打得找不到方向了 中国转向内需就像美国彻底重建制造业一样抽象 发改委认为你不是没钱，是捂着钱袋子不投资不消费，就跟朋友借钱我说没钱死 活不信一摸一样 今天这个发布会啊，没啥新内容，央行再次表态适时降准降息，我真是听够了， 然后说针对部分领域推出新的结构性工具。 发改委说定向增发购车指标、 工业软件升级纳入"两新"政策范围。商务部说为 外贸企业设立信贷支持工具。 说回A股，一看到拉银行，我就知道，今天又白玩！ 今天看到一个篇讲银行的文章，还挺有意思，但是找不到了（微信怎么没有查看 浏览记录的功能，哪位大神知道可以指路一下） 还好我截了一个图，如果从股息率的角度来买银行的话，似乎不太对，因为大行 的股息率不可持续。所以大家都是相信国家队才跟的？ | 银行 | | 2022年股息率(%) 2023年股息率(%) 2024年股息率(%) | | | --- | --- | --- | --- | | 建设银行 | 6.4654 | 5.9754 | 4.5506 | | ...

主力资金净流出的行业有29个，电子行业主力资金净流出规模居首，今日下跌0.44%，全天净流出资金 31.04亿元，其次是汽车行业，今日跌幅为1.59%，净流出资金为25.16亿元，净流出资金较多的还有机 械设备、医药生物、非银金融等行业。 今日各行业资金流向 | 行业 | 日涨跌幅（%） | 资金流向（亿元） | 行业 | 日涨跌幅（%） | 资金流向（亿元） | | --- | --- | --- | --- | --- | --- | | 钢铁 | 0.53 | 2.00 | 商贸零售 | -1.49 | -8.02 | | 石油石化 | -0.03 | 0.67 | 农林牧渔 | -1.20 | -8.02 | | 轻工制造 | -1.25 | -0.22 | 有色金属 | -0.46 | -9.32 | | 建筑材料 | -1.57 | -1.69 | 通信 | -0.75 | -10.19 | | 传媒 | 0.02 | -1.79 | 国防军工 | -1.06 | -10.38 | | 纺织服饰 | -0.90 | -1.90 | 食品饮料 | -0.38 | -10.45 | | 美容护理 | ...

Market Overview - The ChiNext Index fell by 0.65%, closing at 1934.46 points, with a total trading volume of 263.116 billion yuan, a decrease of 28.518 billion yuan from the previous trading day [1] - Among the tradable ChiNext stocks, 303 stocks closed higher, with 9 stocks rising over 10%, while 1062 stocks closed lower, including 24 stocks that fell over 10% [1] Trading Activity - The average turnover rate for the ChiNext today was 3.17%, with 25 stocks having a turnover rate exceeding 20% [1] - C Zhongjie, a new stock listed for 5 days, had the highest turnover rate at 63.74%, closing down 13.43% with a trading volume of 636 million yuan [1][2] - The stocks with significant turnover rates included Zhejiang Huayuan, Jiuzhou Group, and Shaoyang Hydraulic, with turnover rates of 43.58%, 36.96%, and 33.45% respectively [1][2] Institutional Activity - Among the high turnover stocks, 8 were listed on the Dragon and Tiger List, with 6 stocks showing institutional presence [3] - Hongjing Optoelectronics had 4 institutional seats with a net purchase of 57.1991 million yuan, while other stocks like Hengbo and Jiuzhou Group also saw institutional buying [3] Fund Flow - 16 high turnover stocks experienced net inflows from main funds, with Hongjing Optoelectronics, Xinhan New Materials, and Meiri Interactive seeing the largest net inflows of 59.7897 million yuan, 55.9945 million yuan, and 55.7801 million yuan respectively [3] - Conversely, Jiuzhou Group, Zhongzhou Special Materials, and Zhejiang Huayuan faced significant net outflows of 166 million yuan, 108 million yuan, and 75.4195 million yuan respectively [3] Earnings Performance - Among the high turnover stocks, 22 have announced their 2024 annual reports, with notable net profit growth from Lihexing, United Chemical, and Hongjing Optoelectronics, showing increases of 118.76%, 66.81%, and 41.91% respectively [4] - The stock with the highest projected net profit growth is Zhongzhou Special Materials, with an expected increase of 16.50% [4] Summary of High Turnover Stocks - C Zhongjie: Latest closing price 39.91, daily change -13.43%, turnover rate 63.74%, net outflow -27.8543 million yuan [4] - Zhejiang Huayuan: Latest closing price 18.41, daily change -11.91%, turnover rate 43.58%, net outflow -75.4195 million yuan [4] - Hongjing Optoelectronics: Latest closing price 142.98, daily change 20.00%, turnover rate 32.24%, net inflow 59.7897 million yuan [4]

Group 1 - The report indicates that the overall net value of public funds in China decreased to 31.55 trillion yuan as of March 31, 2025, with stock and mixed funds net values at 4.03 trillion yuan and 3.22 trillion yuan, respectively, showing increases of 0.51% and 1.22% compared to the end of 2024 [4][8] - The report highlights that the performance of various types of public funds varied, with an overall return of 2.07% in the first quarter of 2025. QDII funds led with a return of 3.93%, followed by mixed funds at 3.31% and stock funds at 2.93% [4][18] - The technology, pharmaceutical, and consumer sectors received significant attention from funds, with major holdings concentrated in electronics, food and beverage, banking, and non-bank financial sectors. Notable increases in holdings were observed in companies like Alibaba-W, BYD, and Tencent Holdings [4][25] Group 2 - The top 20 heavy-weight stocks primarily belong to the electronics, food and beverage, banking, and non-bank financial sectors, with new entrants like BYD and Alibaba-W, while companies like CITIC Securities and Mindray Medical exited the list [25][26] - The report notes that the electronic sector remains the largest heavy-weight sector for funds, with a holding market value ratio of 7.25%, followed by food and beverage and electric equipment sectors [30] - The report suggests that the investment strategy should focus on sectors like technology and pharmaceuticals, while reducing exposure to financial and cyclical industries, as the technology growth sector continues to attract market interest [5][42]

业绩短期承压，成长动力充足 ——仙琚制药 24 年报&25 年一季报点评 核心观点 盈利预测与投资建议 ⚫ 根据 24 年报，我们下调营业收入预测，预测公司 2025-2027 年每股收益分别为 0.69/0.80/0.97 元（原 2025-2026 年预测为 0.86/1.08 元），根据可比公司，给予公 司 2025 年 16 倍市盈率，对应目标价为 11.04 元，维持"买入"评级。 风险提示 ⚫ 公司原料药、制剂销售不达预期；产品研发审批进度不达预期；市场波动风险等。 公司主要财务信息 | | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入(百万元) | 4,123 | 4,001 | 4,598 | 5,361 | 6,336 | | 同比增长 (%) | -5.9% | -3.0% | 14.9% | 16.6% | 18.2% | | 营业利润(百万元) | 646 | 678 | 855 | 993 | 1,197 | | 同比增长 (%) | -26.4% | 4.9% ...

Investment Rating - The report maintains a "Recommended" rating for the healthcare sector [7] Core Insights - The pharmaceutical sector has shown a slight outperformance against the CSI 300 index, with the Shenwan Pharmaceutical Bio Index rising by 1.16% from April 21 to April 25, 2025, outperforming the CSI 300 by 0.78 percentage points [2][12] - Year-to-date, the Shenwan Pharmaceutical Bio Index has decreased by 0.31%, yet it has outperformed the CSI 300 by 3.45 percentage points, ranking 13th among 31 Shenwan first-level industry indices [2][14] - As of April 25, 2025, the valuation of the pharmaceutical sector stands at 26.37 times (TTM overall method, excluding negative values), with a premium of 141.60% compared to the CSI 300 [2][17] Summary by Sections 1. Market Performance Review - The pharmaceutical sector has shown a mixed performance, with notable individual stock movements, including significant gains for companies like Yong'an Pharmaceutical (+31.37%) and Shutaishen (+28.41%), while companies like *ST Jiyuan experienced substantial declines (-43.24%) [3][18] 2. Important Policies and Events - On April 7, 2025, the Ministry of Commerce and the National Health Commission, among 12 departments, issued the "Special Action Plan to Promote Healthy Consumption," aimed at enhancing the quality of health goods and services to meet the public's needs [4][21] 3. Key Company Announcements - Companies such as Kanghong Pharmaceutical and Yiyue Medical have reported their 2024 annual results, with Kanghong achieving a revenue of 4.453 billion yuan, a year-on-year increase of 12.51%, while Yiyue reported a revenue of 7.566 billion yuan, a decline of 5.09% [22] 4. Industry Perspectives - The report highlights a continued rebound in the pharmaceutical sector, particularly in the innovative drug segment, which is expected to remain a key investment theme for 2025. The focus is shifting from earnings to fundamental changes in the industry and companies as the market enters a performance vacuum period starting in May [5][23][24]